Cite
HARVARD Citation
Verstovsek, S. et al. (n.d.). The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British journal of haematology. pp. 508-516. [Online].